Table 3.
Circulating miRNAs as potential therapy response biomarkers of lung cancer.
| miRNA Signature | Sample Type | Type of Biomarker | Cohort Size | Method of Quantification and Normalization | References |
|---|---|---|---|---|---|
| 199a-3p, miR-21-5p, and miR-28-5p | Plasma | Biomarker for anti-PD-1/PD-L1 antibody therapy response in advanced NSCLC | NSCLC (n = 50), 22 responders and 28 non-responders | Sequencing and qPCR; RPM of processed reads and endogenous miR-30a-5p | Shukuya et al., 2020 [96] |
| Exosomal miRNAs miR-320d, miR-320c, and miR-320b |
Plasma | Biomarker for anti-PD-1/PD-L1 therapy response in EGFR/ALK-negative advanced NSCLC | NSCLC (n = 9), 5 responders and 4 non-responders | Sequencing; not specified |
Peng et al., 2020 [97] |
| miR-93, miR-138- 5p, miR-200, miR-27a, miR-424, miR-34a, miR-28, miR-106b, miR-193a-3p, and miR-181a |
Serum | Biomarker for anti-PD-1 therapy response in EGFR/ALK-negative advanced NSCLC | NSCLC, stage IV (n = 80), 36 responders and 44 non-responders | PCR array and qPCR; not specified and serum volume | Fan et al., 2020 [98] |
| miR-30b and miR-30c | Plasma | Biomarker for erlotinib response in EGFR-mutated NSCLC |
EGFR-mutated NSCLC patients (n = 29) | qPCR; absolute expression |
Hojbjerg et al., 2019 [99] |
NSCLC: non-small-cell lung cancer; PD-1: programmed cell death protein 1; PD-L1: programmed cell death protein 1 ligand; RPM: read count per million; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma receptor tyrosine kinase; EGFR: epidermal growth factor receptor.